Louisiana’s push to halt abortion pills by mail heads back to the Fifth Circuit after a quick trip to the U.S. Supreme Court. An entirely new panel of judges is set to take up the case.
A new program rolled out by the Trump administration that aims to decrease prescription drug prices in the U.S. has been causing consternation among drug companies, which fear the resulting pricing uncertainty could gut licensing deals that were inked long before the program was even on the horizon.
A platform for No Surprises Act disputes could make it easier for medical providers and insurers to track cases. But experts don't expect it will do much to address the fiercest complaints about the system.